
Valiant Organics Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 4
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- FY24 H1 revenue declined 23.6% YoY to Rs. 405 crores due to weak demand and price corrections.
- Volumes increased modestly (~7%) but prices fell ~5%, impacting revenue.
- Chlorination chemistry currently at ~50% utilization; utilization expected to improve if European demand recovers in FY25.
- PAP (Para Amino Phenol) capacity stabilizing; aiming for 600-800 tonnes/month, with ongoing CAPEX (~Rs. 20-30 crores) to achieve scale.
- OAP (Ortho Amino Phenol) expected revenue around Rs. 30 crores at 100 tonnes/month production, though prices remain volatile.
- Overall FY25 expected to be more prosperous with market demand revival, especially from Europe.
- Current low utilization (~50%) at plants; focus on stabilizing existing capacities, not large CAPEX expansion due to underutilization risks.
- Management cautious on margin and revenue guidance due to uncertain market conditions and volatile prices.
See what Valiant Organics management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company is planning to do a CAPEX of around ₹80 to ₹90 crores this year.
- To support this CAPEX, they are looking to retain cash flows and are also considering taking a term loan (debt).
- There is no mention of any immediate or planned equity fundraising.
- Buyback is not planned in the immediate future due to cash flow needs for CAPEX but might be considered going forward.
- No specific details on any fresh equity issuance or large-scale debt raising were disclosed.
See what Valiant Organics management said on order book — free account, 30 seconds.
Capex plans
Yes- Current year CAPEX is around ₹80-90 crores, including maintenance CAPEX of ₹20-30 crores.
- Major CAPEX includes:
- - Process improvements and quality stabilization at existing plants (e.g., Ahmedabad, Sarigam, Tarapur).
- - Debottlenecking and infrastructure upgrades (e.g., ETPs, warehousing).
- - New systems installation like DCS at Tarapur and R&D center at Vapi.
- No major large-scale expansions planned as recent expansions over last 3-4 years were significant.
- Focus currently on stabilizing three ongoing projects rather than adding new capacity.
- PAP project CAPEX approximately ₹270 crores, with payback period previously estimated at 3 years but currently uncertain due to price volatility.
- No immediate plans for buybacks as cash is prioritized for CAPEX and possible term loans are being considered.
- Management prefers to retain cash for ongoing and prioritized CAPEX rather than buybacks in the current market environment.
Track Valiant Organics — get its next earnings analysis in your feed
How does Valiant Organics rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Valiant Organics rank in Chemicals & Petrochemicals?
Compare Valiant Organics against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Valiant Organics's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…